drug
fruquintinib
Marketedupdated 3mo agoby Takeda Pharmaceuticals USA Inc
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 3all catalysts(1)
Trials studying fruquintinib
- phase2A Multicenter, Phase Ib/II Clinical Trial to Evaluate the Efficacy and Safety of Concurrent Combination Therapy of S-531011 Plus Fruquintinib or S-531011 Plus Fruquintinib Plus Pembrolizumab in Patients With MSS/pMMR Colorectal Cancer
- phase3Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies
- phase2Trial of 5-Fluorouracil (5FU)-Based Therapy in Combination With Fruquintinib in Patients With Locally Advanced Unresectable or Metastatic Colorectal Cancer
- phase2A Study to Test DSP107 in Combination With Atezolizumab in Comparison With Fruquintinib as a New Treatment for Colorectal Cancer.
- phase2SHR-3821 in Advanced Colorectal Cancer: an Exploratory Study
- phase2A Phase 2 Trial of Fruquintinib and Tislelizumab in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy
- phase2A Clinical Study of Iparomlimab and Tuvonralimab Combined With Fruquintinib and Heterogeneous Radiotherapy Versus Fruquintinib as Third-Line and Subsequent-Line Treatment for Metastatic Colorectal Cancer
- phase3A Clinical Study to Evaluate Injection TQB2102 for the Treatment of Patients With HER2 IHC3+ Advanced Colorectal Cancer Who Progressed After Treatment With Oxaliplatin, Irinotecan and Fluoropyrimidine-Based Drugs
Patent cliff
source: FDA Orange Bookfirst barrier falls
May 9, 2028
~1.7 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (8)
- Sep 7, 2035compositionUS 10519142
- Sep 7, 2035compositionUS 10519142
- Sep 7, 2035method-of-use (U-3753)US 11046674
- Sep 7, 2035method-of-use (U-3753)US 11046674
- Mar 23, 2032compositionUS 7829574
- Mar 23, 2032compositionUS 7829574
- May 9, 2028method-of-use (U-3753)US 82120331.7y
- May 9, 2028method-of-use (U-3753)US 82120331.7y
FDA exclusivities (2)
- Nov 8, 2028NCENew Chemical Entity (5y)2.2y
- Nov 8, 2028NCENew Chemical Entity (5y)2.2y
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 23m ago
Found something off?
comments(0)
5-min edit window · permanent after that